CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment
2.12.2025 14:30:00 CET | Business Wire | Press release
CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer.
The partnership draws upon CorriXR’s proprietary CRISPR-based gene editing platform targeting NRF2, InhaTarget’s proprietary formulation platform and strong experience in pulmonary drug development, and Merxin Ltd’s advanced inhalation device technology. Through their combined expertise, they aim to create a patient-friendly inhaled therapy that delivers targeted treatment directly to lung tumors, maximizing efficacy, minimizing systemic side effects, and offering new hope for patients facing one of the world’s deadliest cancers.
Innovative Therapeutic Approach
CorriXR’s patented non-viral gene editing platform disables the transcription factor NRF2, a master regulator of cellular stress responses and known driver of tumor treatment resistance. As reported in a recent paper published in Molecular Therapy Oncology, preclinical data in lung cancer models have demonstrated that disabling NRF2 can meaningfully resensitize tumor response to chemotherapy with minimal off-target effects.
The collaboration seeks to demonstrate effective delivery of the CorriXR compound via InhaTarget’s proprietary lipid-nanoparticle (LNP) formulation platform, which enables encapsulation of active ingredients for inhalation delivery. Merxin Ltd will contribute their customized and patented inhaler device technology for drug delivery to the lungs. Initial studies will be conducted in cell culture and in a lung carcinoma mouse model, with results expected in mid-2026.
Addressing Unmet Medical Needs
Lung cancer continues to be one of the leading causes of cancer-related deaths globally. The study will focus on treatment of squamous cell lung carcinoma (LUSC), a common and aggressive form of non-small cell lung cancer (NSCLC) that comprises 25 - 30% of worldwide cases. With over 380,000 new cases of LUSC diagnosed globally each year and a five-year survival rate below 5%, the need for new therapies is urgent. Chemotherapy plus immunotherapy (IO) or IO alone is the current standard for first-line treatment of LUSC but still typically results in progression after 8 months or less. Many patients develop treatment resistance, leaving limited options beyond dose escalation, which increases toxicity and intolerance and typically worsens quality of life.
Leadership Perspectives
Dr. Eric B. Kmiec, founder and CEO of CorriXR Therapeutics, stated, “This partnership represents a significant step forward in our mission to harness the power of CRISPR-based gene editing for the benefit of patients with cancer by slowing the growth of solid tumors and improving effectiveness of existing treatments. We are excited by the potential of this collaboration to target lung cancer using a non-invasive inhaled delivery approach, which would greatly improve the quality of life for patients.”
Dr. Frédéric De Coninck, co-founder and CEO of InhaTarget Therapeutics, commented, “Combining our pulmonary drug delivery LNP platform with CorriXR’s groundbreaking science and Merxin’s device technology has the potential to reshape the landscape of lung cancer treatment. We are eager to advance work on this novel combination.”
Dr. Philippe Rogueda, CBO and founder of Merxin Ltd., remarked, “Our advanced inhaler technology is designed to ensure non-invasive, precise, consistent delivery of novel therapeutics. We are excited to contribute to this vital effort and help bring innovative solutions to patients with lung cancer.”
About the Companies
CorriXR Therapeutics, Inc.
CorriXR develops genetic medicines to transform the treatment of solid tumors. The Company’s patented non-viral gene editing platform targets NRF2, a transcription factor controlling more than 200 genes that shape a pro-oncogenic tumor microenvironment and drive treatment resistance. Disruption of NRF2 resensitizes cancer cells to standard of care therapies and is being developed as a monotherapy and in combination with chemotherapy, radiotherapy or immunotherapy. CorriXR's platform has potential applications across more than 30 types of squamous cell carcinomas by increasing treatment effectiveness and efficiency at lower doses, expanding patient eligibility, and reducing treatment-limiting toxicity — ultimately leading to improved patient outcomes. Learn more at www.corrixr.com.
InhaTarget Therapeutics, SRL
InhaTarget is dedicated to (co-)developing innovative and targeted formulations for inhalation, including dry powders for inhalation (DPI) and liquid forms, to improve the treatment of severe and/or chronic respiratory diseases. The company specializes in early development and clinical validation, with an initial focus on lung cancer. For more information, visit www.inhatarget.com.
Merxin Ltd.
Merxin Ltd is a leading provider of inhalation device technology, offering a comprehensive proprietary and patented portfolio for inhaled therapies. Specializing in multidose dry powder inhalers, capsule dry powder inhalers, and soft mist inhalers, Merxin Ltd’s devices are designed to deliver a wide range of therapeutic modalities. The company develops and supplies device platforms from evaluation to commercial supply. For more information, visit www.merxin.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251202670775/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $750,000,000 Senior Secured Notes by Venture Global Calcasieu Pass, LLC23.4.2026 19:47:00 CEST | Press release
Venture Global, Inc. (“Venture Global”, NYSE: VG) announced today that its subsidiary, Venture Global Calcasieu Pass, LLC (“VGCP”) has closed an offering of $750,000,000 aggregate principal amount of 6.000% senior secured notes due 2036 (the “Notes”). The Notes will mature on May 1, 2036. VGCP used the net proceeds from the offering, together with cash on hand and proceeds received from certain hedge terminations, for the prepayment, in full, of VGCP’s outstanding term loans, and to pay fees and expenses in connection with the offering. The Notes are guaranteed by TransCameron Pipeline, LLC (VGCP’s affiliate). The Notes are secured on a pari passu basis by a first-priority security interest in the assets that secure VGCP’s existing senior secured first lien credit facilities and VGCP’s existing senior secured notes. The Notes were not registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state or other jurisdictions, and the Notes
Does Muscle Composition Identify High-Risk Individuals in Chronic Kidney Disease? New AMRA Medical Study Says Yes, Reveals Strong Link to Mortality23.4.2026 17:10:00 CEST | Press release
AMRA Medical researchers recently set out to answer the question: what is the relationship between adverse muscle composition (AMC) and mortality in kidney disease? Recent findings demonstrate that AMC, characterized by low muscle volume z-score and high muscle fat infiltration, is an independent and strong predictor of all-cause mortality in individuals with chronic kidney disease (CKD). The findings, published in Clinical Journal of the American Society of Nephrology, were based on data from the UK Biobank imaging study and further reinforce the clinical relevance of MRI-derived muscle biomarkers in identifying high-risk populations across chronic diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423198497/en/ AMRA's MRI-based muscle biomarkers in clinical trials Researchers from AMRA, alongside our collaborators at Linköping University (LiU), analyzed 894 participants with CKD using AMRA’s MRI-based body composi
Diligent Unveils AI Board Member and Agentic GRC Workforce at Elevate 202623.4.2026 15:00:00 CEST | Press release
Diligent’s agentic AI strengthens board oversight and transforms how GRC teams work — reducing manual effort and outside-advisor dependency, tightening control over sensitive workflows and enabling leaders to make faster, more defensible decisions Diligent, the AI leader in governance, risk and compliance (GRC) SaaS solutions, today unveiled a new generation of autonomous AI agents, including AI Board Member — a secure AI assistant for directors — and a coordinated network of agents embedded across the Diligent One Platform. Accessible through a single command center, agents automate multi-step workflows across governance, risk, compliance and third-party management, giving organizations the impact of a “GRC manager” without adding headcount. “AI supercharges teams that embrace it, and boards are no exception,” said Brian Stafford, President and CEO of Diligent. “With AI Board Member and a network of autonomous agents woven through the Diligent One Platform, we’re giving the C-suite an
Safe Software Bolsters Leadership Team with CFO and CPO Appointments to Drive Next Phase of Growth23.4.2026 15:00:00 CEST | Press release
CFO and CPO executive hires to enhance operational and financial performance on the company’s path to $250M by 2028 Safe Software (Safe), creator of FME, the only All-Data, Any-AI enterprise integration platform, today welcomes two executives to its leadership team as it moves into the next phase of growth. Judd Lee has been appointed as the company’s Chief Financial Officer (CFO), and Vanessa Ribreau has been appointed as Chief People Officer (CPO). Having recently crossed $100M in revenue, the expanded leadership team will further enable the company to scale as it accelerates toward its goal of reaching $250M in revenue by 2028. Judd Lee is a seasoned CFO with over 15 years of experience partnering closely with CEOs to align financial strategy and accelerate sustainable growth. He is known for his strong commitment to mentorship and for building high-performing global teams rooted in trust, morale and a shared sense of purpose. With more than two decades of financial leadership acros
Corpay Cross-Border Named the Official FX Supplier of Toulouse Football Club23.4.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Toulouse Football Club to become their Official Foreign Exchange (FX) Supplier. A partnership brought together by SPORTFIVE, an international sports marketing agency. Through this partnership, Corpay Cross-Border will deliver comprehensive FX risk management solutions to support Toulouse Football Club’s operations. In addition, its award-winning platform will enable the club to manage global payments seamlessly through a single point of access. “Corpay Cross-Border is proud to be named the Official FX Supplier of Toulouse Football Club,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership reinforces Corpay’s position as a leading provider of corporate payments and currency risk management solutions within prof
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom